US Patent Issued to LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE on April 14 for "Beta-catenin and b-cell lymphoma 9 (BCL9) inhibitors" (Florida Inventor)

ALEXANDRIA, Va., April 15 -- United States Patent no. 12,600,710, issued on April 14, was assigned to LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. (Tampa, Fla.).

"Beta-catenin and b-cell lymphoma 9 (BCL9) inhibitors" was invented by Haitao Ji (Tampa, Fla.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed are inhibitors for the Beta-catenin/BCL9 interaction. The inhibitors are selective for Beta-catenin/BCL9 over Beta-catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed."

The patent was filed on Oct. 18, 2019, under Application No. 17/286,716.

*For further information, including images, charts and tables, please visit: http://patft.uspto....